Then why, in your opinion, does it remain unvalued by the market?
petemantx Tuesday, 05/13/14 08:06:36 PM Re: alexwv post# 60011 Post # of 60013 I don't agree as to B being tarnished, medically speaking, by Poly bankruptcy. B stands alone based on it's prior clinical trial success, not on the corporate management that couldn't do their job. B was very successful in trials, it is still viewed as an excellent product, and the only difference is who now handles the product. Bottom line - it is even stronger now than when Poly (with it's pitiful mgt) managed it.
As always, in my opinion only. Do your own due diligence!